[1] It was developed by Doctors Neville, Woo, and Liu while at the National Institutes of Health (NIH) and is under exclusive license to Angimmune, LLC.
Since 2009, Resimmune is being tested against cutaneous T cell lymphoma, and is in a Phase II trial: A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases.
A major exclusion to entering the trial is a past history of heart disease, or prior treatment with alemtuzumab (Campath).
[4]: Paragraph 12 A second clinical trial is open to test if Resimmune can act as an immunomodulator of late stage metastatic melanoma.
[6] The diphtheria toxin moiety has been modified to include an NH2-terminal alanine (A) and two double mutations (dm) have been made to prevent glycosylation in the eukaryotic expression system, Pichia pastoris.[7][8][9]).